Literature DB >> 30503774

Dynamics of Cas10 Govern Discrimination between Self and Non-self in Type III CRISPR-Cas Immunity.

Ling Wang1, Charlie Y Mo2, Michael R Wasserman1, Jakob T Rostøl2, Luciano A Marraffini2, Shixin Liu3.   

Abstract

Adaptive immune systems must accurately distinguish between self and non-self in order to defend against invading pathogens while avoiding autoimmunity. Type III CRISPR-Cas systems employ guide RNA to recognize complementary RNA targets, which triggers the degradation of both the invader's transcripts and their template DNA. These systems can broadly eliminate foreign targets with multiple mutations but circumvent damage to the host genome. To explore the molecular basis for these features, we use single-molecule fluorescence microscopy to study the interaction between a type III-A ribonucleoprotein complex and various RNA substrates. We find that Cas10-the DNase effector of the complex-displays rapid conformational fluctuations on foreign RNA targets, but is locked in a static configuration on self RNA. Target mutations differentially modulate Cas10 dynamics and tune the CRISPR interference activity in vivo. These findings highlight the central role of the internal dynamics of CRISPR-Cas complexes in self versus non-self discrimination and target specificity.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cas10; adaptive immunity; conformational dynamics; crRNA tag; protospacer; self/non-self discrimination; single-molecule FRET; target specificity; type III CRISPR-Cas

Mesh:

Substances:

Year:  2018        PMID: 30503774      PMCID: PMC6338483          DOI: 10.1016/j.molcel.2018.11.008

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  62 in total

1.  Structure basis for RNA-guided DNA degradation by Cascade and Cas3.

Authors:  Yibei Xiao; Min Luo; Adam E Dolan; Maofu Liao; Ailong Ke
Journal:  Science       Date:  2018-06-07       Impact factor: 47.728

2.  RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions.

Authors:  Blake Wiedenheft; Esther van Duijn; Jelle B Bultema; Jelle Bultema; Sakharam P Waghmare; Sakharam Waghmare; Kaihong Zhou; Arjan Barendregt; Wiebke Westphal; Albert J R Heck; Albert Heck; Egbert J Boekema; Egbert Boekema; Mark J Dickman; Mark Dickman; Jennifer A Doudna
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

3.  A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems.

Authors:  Migle Kazlauskiene; Georgij Kostiuk; Česlovas Venclovas; Gintautas Tamulaitis; Virginijus Siksnys
Journal:  Science       Date:  2017-06-29       Impact factor: 47.728

4.  Broad Targeting Specificity during Bacterial Type III CRISPR-Cas Immunity Constrains Viral Escape.

Authors:  Nora C Pyenson; Kaitlyn Gayvert; Andrew Varble; Olivier Elemento; Luciano A Marraffini
Journal:  Cell Host Microbe       Date:  2017-08-17       Impact factor: 21.023

Review 5.  Diversity, classification and evolution of CRISPR-Cas systems.

Authors:  Eugene V Koonin; Kira S Makarova; Feng Zhang
Journal:  Curr Opin Microbiol       Date:  2017-06-09       Impact factor: 7.934

6.  Assembly and Translocation of a CRISPR-Cas Primed Acquisition Complex.

Authors:  Kaylee E Dillard; Maxwell W Brown; Nicole V Johnson; Yibei Xiao; Adam Dolan; Erik Hernandez; Samuel D Dahlhauser; Yoori Kim; Logan R Myler; Eric V Anslyn; Ailong Ke; Ilya J Finkelstein
Journal:  Cell       Date:  2018-10-18       Impact factor: 41.582

7.  Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity.

Authors:  Jing Zhang; Christophe Rouillon; Melina Kerou; Judith Reeks; Kim Brugger; Shirley Graham; Julia Reimann; Giuseppe Cannone; Huanting Liu; Sonja-Verena Albers; James H Naismith; Laura Spagnolo; Malcolm F White
Journal:  Mol Cell       Date:  2012-01-05       Impact factor: 17.970

8.  Self versus non-self discrimination during CRISPR RNA-directed immunity.

Authors:  Luciano A Marraffini; Erik J Sontheimer
Journal:  Nature       Date:  2010-01-13       Impact factor: 49.962

9.  Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system.

Authors:  Joshua R Elmore; Nolan F Sheppard; Nancy Ramia; Trace Deighan; Hong Li; Rebecca M Terns; Michael P Terns
Journal:  Genes Dev       Date:  2016-02-04       Impact factor: 11.361

10.  Control of cyclic oligoadenylate synthesis in a type III CRISPR system.

Authors:  Christophe Rouillon; Januka S Athukoralage; Shirley Graham; Sabine Grüschow; Malcolm F White
Journal:  Elife       Date:  2018-07-02       Impact factor: 8.140

View more
  18 in total

1.  Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity.

Authors:  Ning Jia; Charlie Y Mo; Chongyuan Wang; Edward T Eng; Luciano A Marraffini; Dinshaw J Patel
Journal:  Mol Cell       Date:  2018-11-29       Impact factor: 17.970

2.  Characterization of a novel type III CRISPR-Cas effector provides new insights into the allosteric activation and suppression of the Cas10 DNase.

Authors:  Jinzhong Lin; Mingxia Feng; Heping Zhang; Qunxin She
Journal:  Cell Discov       Date:  2020-05-12       Impact factor: 10.849

3.  Second Messenger cA4 Formation within the Composite Csm1 Palm Pocket of Type III-A CRISPR-Cas Csm Complex and Its Release Path.

Authors:  Ning Jia; Roger Jones; George Sukenick; Dinshaw J Patel
Journal:  Mol Cell       Date:  2019-07-17       Impact factor: 17.970

4.  A seed motif for target RNA capture enables efficient immune defence by a type III-B CRISPR-Cas system.

Authors:  Saifu Pan; Qi Li; Ling Deng; Suping Jiang; Xuexia Jin; Nan Peng; Yunxiang Liang; Qunxin She; Yingjun Li
Journal:  RNA Biol       Date:  2019-05-26       Impact factor: 4.652

5.  Target sequence requirements of a type III-B CRISPR-Cas immune system.

Authors:  Kaitlin Johnson; Brian A Learn; Michael A Estrella; Scott Bailey
Journal:  J Biol Chem       Date:  2019-05-19       Impact factor: 5.157

6.  CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells.

Authors:  Ping Lin; Shugang Qin; Qinqin Pu; Zhihan Wang; Qun Wu; Pan Gao; Jacob Schettler; Kai Guo; Rongpeng Li; Guoping Li; Canhua Huang; Yuquan Wei; George Fu Gao; Jianxin Jiang; Min Wu
Journal:  Mol Cell       Date:  2020-04-28       Impact factor: 17.970

7.  Allosteric control of type I-A CRISPR-Cas3 complexes and establishment as effective nucleic acid detection and human genome editing tools.

Authors:  Chunyi Hu; Dongchun Ni; Ki Hyun Nam; Sonali Majumdar; Justin McLean; Henning Stahlberg; Michael P Terns; Ailong Ke
Journal:  Mol Cell       Date:  2022-07-13       Impact factor: 19.328

Review 8.  RNA-targeting CRISPR-Cas systems.

Authors:  Sam P B van Beljouw; Jasper Sanders; Alicia Rodríguez-Molina; Stan J J Brouns
Journal:  Nat Rev Microbiol       Date:  2022-09-28       Impact factor: 78.297

9.  Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses.

Authors:  Ping Lin; Guanwang Shen; Kai Guo; Shugang Qin; Qinqin Pu; Zhihan Wang; Pan Gao; Zhenwei Xia; Nadeem Khan; Jianxin Jiang; Qingyou Xia; Min Wu
Journal:  Nucleic Acids Res       Date:  2022-05-06       Impact factor: 19.160

10.  Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.

Authors:  Kawanda Foster; Sabine Grüschow; Scott Bailey; Malcolm F White; Michael P Terns
Journal:  Nucleic Acids Res       Date:  2020-05-07       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.